Review



polyclonal antibodies  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    R&D Systems polyclonal antibodies
    Polyclonal Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/Human+PlGF+Biotinylated+Antibody/us12441765-145-11-13
    Average 92 stars, based on 10 article reviews
    polyclonal antibodies - by Bioz Stars, 2026-09
    92/100 stars

    Images

    Related Articles

    Binding Assay:

    Article Title: Determination of sFlt-1:angiogenic factor complex
    Article Snippet: .. Biotinylated anti-PlGF antibodies capable of binding to sFlt-1:PlGF complex include but are not limited to Ortho-Clinical Diagnostic's mouse monoclonal antibody OCD-261 and rat monoclonal antibodies 358905 and 358932 available from R&D Systems, Minneapolis, Minn. 2. ..

    Article Title: Determination of sFlt-1:angiogenic factor complex
    Article Snippet: .. Biotinylated anti-PlGF antibodies capable of binding to sFlt-1:PlGF complex include but are not limited to Ortho-Clinical Diagnostic's mouse monoclonal antibody OCD-261 and rat monoclonal antibodies 358905 and 358932 available from R&D Systems, Minneapolis, Minn. 2. ..

    Bioprocessing:

    Article Title: Determination of sFlt-1:angiogenic factor complex
    Article Snippet: .. Biotinylated anti-PlGF antibodies capable of binding to sFlt-1:PlGF complex include but are not limited to Ortho-Clinical Diagnostic's mouse monoclonal antibody OCD-261 and rat monoclonal antibodies 358905 and 358932 available from R&D Systems, Minneapolis, Minn. 2. ..

    Article Title: Determination of sFlt-1:angiogenic factor complex
    Article Snippet: .. Biotinylated anti-PlGF antibodies capable of binding to sFlt-1:PlGF complex include but are not limited to Ortho-Clinical Diagnostic's mouse monoclonal antibody OCD-261 and rat monoclonal antibodies 358905 and 358932 available from R&D Systems, Minneapolis, Minn. 2. ..



    Similar Products

    92
    R&D Systems polyclonal antibodies
    Polyclonal Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/Human+PlGF+Biotinylated+Antibody/us12441765-145-11-13
    Average 92 stars, based on 1 article reviews
    polyclonal antibodies - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    92
    R&D Systems anti hplgf
    Anti Hplgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/Human+PlGF+Biotinylated+Antibody/pm33434889-69-19-21
    Average 92 stars, based on 1 article reviews
    anti hplgf - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    93
    R&D Systems biotinylated polyclonal goat anti human plgf iggs
    Biotinylated Polyclonal Goat Anti Human Plgf Iggs, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/Human+PlGF+Biotinylated+Antibody/pm32485280-79-52-66
    Average 93 stars, based on 1 article reviews
    biotinylated polyclonal goat anti human plgf iggs - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    92
    R&D Systems human plgf
    Recombinant <t>PlGF</t> has <t>specific</t> <t>affinity</t> with its mAb (PL5D11D4) and disrupts HREC barrier function. A, B) Dot immunoassay demonstrated the specific affinity of PlGF antibody (PL5D11D4) with rbPlGF (A) and rhPlGF (B). rhVEGF and BSA acted as negative controls. HRP, horseradish peroxidase. C) HRECs were cultured and grown with endothelial growth medium 2 (EGM-2) (with growth factors such as VEGF-A). After the cells grew to confluence, the culture medium was changed to endothelial cell growth basal medium 2 (EBM-2) (without growth factors), and PBS control and rhPlGF protein (100 ng/ml) were added to the culture medium and incubated for at least 2 d. TEER was monitored by an ECIS system at an AC frequency of 4 KHz in real time. TEER curves of HRECs that were treated with rhPlGF protein and PBS control. Error bars represent sd out of 4 duplicate samples. The experiments were repeated at least 3 times. D) WB result for VE-cadherin, β-catenin, and ZO-1. β-Actin was used as the protein loading control. E, F) Immunofluorescence staining results of tight junction ZO-1 and adhesion protein VE-cadherin. ****P < 0.0001.
    Human Plgf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/Human+PlGF+Biotinylated+Antibody/pmc06894064-78-26-33
    Average 92 stars, based on 1 article reviews
    human plgf - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    90
    R&D Systems biotin
    Recombinant <t>PlGF</t> has <t>specific</t> <t>affinity</t> with its mAb (PL5D11D4) and disrupts HREC barrier function. A, B) Dot immunoassay demonstrated the specific affinity of PlGF antibody (PL5D11D4) with rbPlGF (A) and rhPlGF (B). rhVEGF and BSA acted as negative controls. HRP, horseradish peroxidase. C) HRECs were cultured and grown with endothelial growth medium 2 (EGM-2) (with growth factors such as VEGF-A). After the cells grew to confluence, the culture medium was changed to endothelial cell growth basal medium 2 (EBM-2) (without growth factors), and PBS control and rhPlGF protein (100 ng/ml) were added to the culture medium and incubated for at least 2 d. TEER was monitored by an ECIS system at an AC frequency of 4 KHz in real time. TEER curves of HRECs that were treated with rhPlGF protein and PBS control. Error bars represent sd out of 4 duplicate samples. The experiments were repeated at least 3 times. D) WB result for VE-cadherin, β-catenin, and ZO-1. β-Actin was used as the protein loading control. E, F) Immunofluorescence staining results of tight junction ZO-1 and adhesion protein VE-cadherin. ****P < 0.0001.
    Biotin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/Mouse+PlGF-2+Biotinylated+Antibody/pmc06932757-231-2-6
    Average 90 stars, based on 1 article reviews
    biotin - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    R&D Systems anti plgf2 antibody
    Recombinant <t>PlGF</t> has <t>specific</t> <t>affinity</t> with its mAb (PL5D11D4) and disrupts HREC barrier function. A, B) Dot immunoassay demonstrated the specific affinity of PlGF antibody (PL5D11D4) with rbPlGF (A) and rhPlGF (B). rhVEGF and BSA acted as negative controls. HRP, horseradish peroxidase. C) HRECs were cultured and grown with endothelial growth medium 2 (EGM-2) (with growth factors such as VEGF-A). After the cells grew to confluence, the culture medium was changed to endothelial cell growth basal medium 2 (EBM-2) (without growth factors), and PBS control and rhPlGF protein (100 ng/ml) were added to the culture medium and incubated for at least 2 d. TEER was monitored by an ECIS system at an AC frequency of 4 KHz in real time. TEER curves of HRECs that were treated with rhPlGF protein and PBS control. Error bars represent sd out of 4 duplicate samples. The experiments were repeated at least 3 times. D) WB result for VE-cadherin, β-catenin, and ZO-1. β-Actin was used as the protein loading control. E, F) Immunofluorescence staining results of tight junction ZO-1 and adhesion protein VE-cadherin. ****P < 0.0001.
    Anti Plgf2 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/Mouse+PlGF-2+Biotinylated+Antibody/pmc06932757-231-3-6
    Average 90 stars, based on 1 article reviews
    anti plgf2 antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    90
    Quidel biotinylated anti-plgf antibody
    Recombinant <t>PlGF</t> has <t>specific</t> <t>affinity</t> with its mAb (PL5D11D4) and disrupts HREC barrier function. A, B) Dot immunoassay demonstrated the specific affinity of PlGF antibody (PL5D11D4) with rbPlGF (A) and rhPlGF (B). rhVEGF and BSA acted as negative controls. HRP, horseradish peroxidase. C) HRECs were cultured and grown with endothelial growth medium 2 (EGM-2) (with growth factors such as VEGF-A). After the cells grew to confluence, the culture medium was changed to endothelial cell growth basal medium 2 (EBM-2) (without growth factors), and PBS control and rhPlGF protein (100 ng/ml) were added to the culture medium and incubated for at least 2 d. TEER was monitored by an ECIS system at an AC frequency of 4 KHz in real time. TEER curves of HRECs that were treated with rhPlGF protein and PBS control. Error bars represent sd out of 4 duplicate samples. The experiments were repeated at least 3 times. D) WB result for VE-cadherin, β-catenin, and ZO-1. β-Actin was used as the protein loading control. E, F) Immunofluorescence staining results of tight junction ZO-1 and adhesion protein VE-cadherin. ****P < 0.0001.
    Biotinylated Anti Plgf Antibody, supplied by Quidel, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/biotinylated+anti+plgf+antibodies/mouse+monoclonal+antibody/us09128099-344-2-5
    Average 90 stars, based on 1 article reviews
    biotinylated anti-plgf antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    Image Search Results


    Recombinant PlGF has specific affinity with its mAb (PL5D11D4) and disrupts HREC barrier function. A, B) Dot immunoassay demonstrated the specific affinity of PlGF antibody (PL5D11D4) with rbPlGF (A) and rhPlGF (B). rhVEGF and BSA acted as negative controls. HRP, horseradish peroxidase. C) HRECs were cultured and grown with endothelial growth medium 2 (EGM-2) (with growth factors such as VEGF-A). After the cells grew to confluence, the culture medium was changed to endothelial cell growth basal medium 2 (EBM-2) (without growth factors), and PBS control and rhPlGF protein (100 ng/ml) were added to the culture medium and incubated for at least 2 d. TEER was monitored by an ECIS system at an AC frequency of 4 KHz in real time. TEER curves of HRECs that were treated with rhPlGF protein and PBS control. Error bars represent sd out of 4 duplicate samples. The experiments were repeated at least 3 times. D) WB result for VE-cadherin, β-catenin, and ZO-1. β-Actin was used as the protein loading control. E, F) Immunofluorescence staining results of tight junction ZO-1 and adhesion protein VE-cadherin. ****P < 0.0001.

    Journal: The FASEB Journal

    Article Title: Placental growth factor negatively regulates retinal endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems

    doi: 10.1096/fj.201901353R

    Figure Lengend Snippet: Recombinant PlGF has specific affinity with its mAb (PL5D11D4) and disrupts HREC barrier function. A, B) Dot immunoassay demonstrated the specific affinity of PlGF antibody (PL5D11D4) with rbPlGF (A) and rhPlGF (B). rhVEGF and BSA acted as negative controls. HRP, horseradish peroxidase. C) HRECs were cultured and grown with endothelial growth medium 2 (EGM-2) (with growth factors such as VEGF-A). After the cells grew to confluence, the culture medium was changed to endothelial cell growth basal medium 2 (EBM-2) (without growth factors), and PBS control and rhPlGF protein (100 ng/ml) were added to the culture medium and incubated for at least 2 d. TEER was monitored by an ECIS system at an AC frequency of 4 KHz in real time. TEER curves of HRECs that were treated with rhPlGF protein and PBS control. Error bars represent sd out of 4 duplicate samples. The experiments were repeated at least 3 times. D) WB result for VE-cadherin, β-catenin, and ZO-1. β-Actin was used as the protein loading control. E, F) Immunofluorescence staining results of tight junction ZO-1 and adhesion protein VE-cadherin. ****P < 0.0001.

    Article Snippet: Dot immunoblotting assay Modification of the Dot immunoblotting assay ( 23 , 24 ) was used to validate the affinity and specificity of PL5DLLD4 antibody with human PlGF. rhPlGF protein (200 ng; 264-PGB-010/CF; R&D Systems), VEGF-165 (200 ng, 293-VE-010/CF; R&D Systems), and 500 ng bovine serum albumin (BSA) (MilliporeSigma) were deposited in the volume of 2 μl on dry nitrocellulose membrane (Bio-Rad) and immobilized by 15 min incubation at room temperature The membranes were blocked with 5% nonfat milk (Bio-Rad) in PBS at room temperature for 1 h and then incubated overnight at 4°C with mouse PL5DLLD4 antibody 0.5 μg/ml.

    Techniques: Recombinant, Cell Culture, Control, Incubation, Immunofluorescence, Staining

    PlGF regulates G6PD, PRDX6, and EC barrier function through VEGFR1 and VEGFR2 signaling. A) WB results for G6PD. HRECs that were treated with rhPlGF and VEGF-165 protein (100 ng/ml each, for 2 d) were used for the WB assay: β-actin was used as the protein loading control. Note that rhPlGF, but not VEGF-165, down-regulated the protein level of G6PD compared with the PBS control. B) Double immunofluorescence labeling of G6PD and PRDX6. The HRECs that were treated with the PBS control, rhVEGF(a), and rhPlGF protein were fixed and stained with G6PD (green) and PRDX6 (red). The DAPI staining of the nucleus (blue) was used as the counterstaining. Note that the 2 proteins were colocalized in the PBS-treated and rhVEGF-treated cells (yellow); however, the staining signals were reduced in the rhPlGF-treated cells. The complete images of all 3 fluorescent staining channels are shown in Supplemental Fig. S5. C) WB results of ZO-1, VE-cadherin, and β-catenin. The confluent HRECs were treated with PBS, PBS + rhPlGF (100 ng/ml), rhPlGF + VEGFR1 antibodies (100 µg/ml), rhPlGF + VEGFR2 antibody (100 µg/ml), and VEGFR1 antibody alone or VEGFR2 antibody alone for 2 d. Note that rhPlGF protein down-regulated the protein levels of ZO-1, VE-cadherin, and G6PD, which were prevented by the VEGFR1 or VEGFR2 antibody. The antibody alone did not change the protein levels, which were equivalent to those of the PBS control. D) WB results of ZO-1, VE-cadherin, β-catenin, occludin-1, claudin-5, and G6PD. The confluent HRECs were treated with the PBS, PlGF/VEGF heterodimer (50, 100, or 200 ng/ml), PlGF (100 ng/ml), or VEGF-165 (100 ng/ml). Note that PlGF, the PlGF/VEGF heterodimer (200 ng/ml), and VEGF-165 down-regulated ZO-1, VE-cadherin, β-catenin, and claudin-5 (but not occludin-1); however, only PlGF and PlGF/VEGF down-regulated G6PD. E) TEER (or resistance) of HRECs. After the HRECs grew to confluence, the PBS control, PlGF/VEGF, or VEGF-165 was added to the medium, and the TEER was measured with ECIS in real time. The TEER values of the PlGF/VEGF heterodimer (blue) and VEGF-165 (purple) were significantly lower than those of the PBS control (red). Error bars represent sd out of 4 duplicate samples. F) WB results of PlGF/VEGF heterodimers in HREC lysate and culture medium. The confluent HRECs were treated with PBS, 25 mM d-glucose [high glucose (HG)], and 25 mM l-glucose [normal glucose (NG)]. Note that compared with the PBS controls, the HG up-regulated PlGF/VEGF in the cell lysates but decreased the levels in the culture medium. The β-actin was presented in the HREC lysate (but not in the culture medium) and used as the protein loading control. ****P < 0.0001.

    Journal: The FASEB Journal

    Article Title: Placental growth factor negatively regulates retinal endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems

    doi: 10.1096/fj.201901353R

    Figure Lengend Snippet: PlGF regulates G6PD, PRDX6, and EC barrier function through VEGFR1 and VEGFR2 signaling. A) WB results for G6PD. HRECs that were treated with rhPlGF and VEGF-165 protein (100 ng/ml each, for 2 d) were used for the WB assay: β-actin was used as the protein loading control. Note that rhPlGF, but not VEGF-165, down-regulated the protein level of G6PD compared with the PBS control. B) Double immunofluorescence labeling of G6PD and PRDX6. The HRECs that were treated with the PBS control, rhVEGF(a), and rhPlGF protein were fixed and stained with G6PD (green) and PRDX6 (red). The DAPI staining of the nucleus (blue) was used as the counterstaining. Note that the 2 proteins were colocalized in the PBS-treated and rhVEGF-treated cells (yellow); however, the staining signals were reduced in the rhPlGF-treated cells. The complete images of all 3 fluorescent staining channels are shown in Supplemental Fig. S5. C) WB results of ZO-1, VE-cadherin, and β-catenin. The confluent HRECs were treated with PBS, PBS + rhPlGF (100 ng/ml), rhPlGF + VEGFR1 antibodies (100 µg/ml), rhPlGF + VEGFR2 antibody (100 µg/ml), and VEGFR1 antibody alone or VEGFR2 antibody alone for 2 d. Note that rhPlGF protein down-regulated the protein levels of ZO-1, VE-cadherin, and G6PD, which were prevented by the VEGFR1 or VEGFR2 antibody. The antibody alone did not change the protein levels, which were equivalent to those of the PBS control. D) WB results of ZO-1, VE-cadherin, β-catenin, occludin-1, claudin-5, and G6PD. The confluent HRECs were treated with the PBS, PlGF/VEGF heterodimer (50, 100, or 200 ng/ml), PlGF (100 ng/ml), or VEGF-165 (100 ng/ml). Note that PlGF, the PlGF/VEGF heterodimer (200 ng/ml), and VEGF-165 down-regulated ZO-1, VE-cadherin, β-catenin, and claudin-5 (but not occludin-1); however, only PlGF and PlGF/VEGF down-regulated G6PD. E) TEER (or resistance) of HRECs. After the HRECs grew to confluence, the PBS control, PlGF/VEGF, or VEGF-165 was added to the medium, and the TEER was measured with ECIS in real time. The TEER values of the PlGF/VEGF heterodimer (blue) and VEGF-165 (purple) were significantly lower than those of the PBS control (red). Error bars represent sd out of 4 duplicate samples. F) WB results of PlGF/VEGF heterodimers in HREC lysate and culture medium. The confluent HRECs were treated with PBS, 25 mM d-glucose [high glucose (HG)], and 25 mM l-glucose [normal glucose (NG)]. Note that compared with the PBS controls, the HG up-regulated PlGF/VEGF in the cell lysates but decreased the levels in the culture medium. The β-actin was presented in the HREC lysate (but not in the culture medium) and used as the protein loading control. ****P < 0.0001.

    Article Snippet: Dot immunoblotting assay Modification of the Dot immunoblotting assay ( 23 , 24 ) was used to validate the affinity and specificity of PL5DLLD4 antibody with human PlGF. rhPlGF protein (200 ng; 264-PGB-010/CF; R&D Systems), VEGF-165 (200 ng, 293-VE-010/CF; R&D Systems), and 500 ng bovine serum albumin (BSA) (MilliporeSigma) were deposited in the volume of 2 μl on dry nitrocellulose membrane (Bio-Rad) and immobilized by 15 min incubation at room temperature The membranes were blocked with 5% nonfat milk (Bio-Rad) in PBS at room temperature for 1 h and then incubated overnight at 4°C with mouse PL5DLLD4 antibody 0.5 μg/ml.

    Techniques: Control, Immunofluorescence, Labeling, Staining

    Schematic diagram illustrating that PlGF signaling regulates EC barrier function through G6PD/PPP. PlGF/VEGFR1 or PlGF/VEGF-VEGFR1/R2 signaling regulates EC barrier function (e.g., tight junction and adherens junction proteins) through G6PD/PPP and antioxidant. The regulatory mechanism that VEGF-VEGFR2 signaling regulates EC barrier function or vascular permeability is different. The intracellular molecules that mediate the signaling transduction are unclear.

    Journal: The FASEB Journal

    Article Title: Placental growth factor negatively regulates retinal endothelial cell barrier function through suppression of glucose-6-phosphate dehydrogenase and antioxidant defense systems

    doi: 10.1096/fj.201901353R

    Figure Lengend Snippet: Schematic diagram illustrating that PlGF signaling regulates EC barrier function through G6PD/PPP. PlGF/VEGFR1 or PlGF/VEGF-VEGFR1/R2 signaling regulates EC barrier function (e.g., tight junction and adherens junction proteins) through G6PD/PPP and antioxidant. The regulatory mechanism that VEGF-VEGFR2 signaling regulates EC barrier function or vascular permeability is different. The intracellular molecules that mediate the signaling transduction are unclear.

    Article Snippet: Dot immunoblotting assay Modification of the Dot immunoblotting assay ( 23 , 24 ) was used to validate the affinity and specificity of PL5DLLD4 antibody with human PlGF. rhPlGF protein (200 ng; 264-PGB-010/CF; R&D Systems), VEGF-165 (200 ng, 293-VE-010/CF; R&D Systems), and 500 ng bovine serum albumin (BSA) (MilliporeSigma) were deposited in the volume of 2 μl on dry nitrocellulose membrane (Bio-Rad) and immobilized by 15 min incubation at room temperature The membranes were blocked with 5% nonfat milk (Bio-Rad) in PBS at room temperature for 1 h and then incubated overnight at 4°C with mouse PL5DLLD4 antibody 0.5 μg/ml.

    Techniques: Permeability, Transduction